• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

NAFLD-Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse.

作者信息

Debes Jose D, Boonstra Andre, de Knegt Robert J

机构信息

Department of Medicine, University of Minnesota, Minneapolis, MN.

Department of Gastroenterology & Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

出版信息

Hepatology. 2020 Mar;71(3):774-776. doi: 10.1002/hep.31170. Epub 2020 Mar 4.

DOI:10.1002/hep.31170
PMID:32039490
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7135940/
Abstract
摘要

相似文献

1
NAFLD-Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse.非酒精性脂肪性肝病相关肝细胞癌与启示录四骑士
Hepatology. 2020 Mar;71(3):774-776. doi: 10.1002/hep.31170. Epub 2020 Mar 4.
2
Reply to: "Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease".回复：“多基因风险评分：非酒精性脂肪性肝病患者肝细胞癌的一种有前景的预测指标”
J Hepatol. 2021 Jun;74(6):1494-1496. doi: 10.1016/j.jhep.2021.02.030. Epub 2021 Mar 5.
3
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.非酒精性脂肪性肝病/非酒精性脂肪性肝炎与肝细胞癌。
Clin Liver Dis. 2018 Feb;22(1):201-211. doi: 10.1016/j.cld.2017.08.014.
4
Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.非酒精性脂肪性肝病患者与非非酒精性脂肪性肝病患者在接受肝细胞癌根治性治疗后的生存率。
Aliment Pharmacol Ther. 2017 Dec;46(11-12):1061-1069. doi: 10.1111/apt.14342. Epub 2017 Sep 28.
5
Hepatocellular carcinoma and non-alcoholic fatty liver disease.肝细胞癌与非酒精性脂肪性肝病。
Hepatol Int. 2019 Nov;13(6):688-694. doi: 10.1007/s12072-019-09995-8. Epub 2019 Nov 7.
6
NAFLD as a risk factor for HCC: new rules of engagement?非酒精性脂肪性肝病作为肝细胞癌的危险因素：新的作用机制？
Hepatol Int. 2016 Jul;10(4):533-4. doi: 10.1007/s12072-016-9731-8. Epub 2016 May 5.
7
Letter to the Editor: Consider More Factors When Studying Risk of Cirrhosis and Hepatocellular Cancer in Patients With Nonalcoholic Fatty Liver Disease.致编辑的信：在研究非酒精性脂肪性肝病患者的肝硬化和肝细胞癌风险时应考虑更多因素。
Hepatology. 2020 Jun;71(6):2172-2173. doi: 10.1002/hep.31075.
8
Letter to the Editor: Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Steatohepatitis Cirrhosis and Diabetes: Insufficient for Individual Management.致编辑的信：非酒精性脂肪性肝炎肝硬化合并糖尿病患者的肝细胞癌风险：个体管理依据不足
Hepatology. 2020 Jul;72(1):361-362. doi: 10.1002/hep.31100.
9
Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.乙型肝炎核心抗体阳性与非酒精性脂肪性肝病患者的肝硬化和肝细胞癌相关。
Am J Gastroenterol. 2020 Jun;115(6):867-875. doi: 10.14309/ajg.0000000000000588.
10
Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.20年间接受肝切除手术的非酒精性脂肪性肝病相关肝癌患者的时间趋势、临床模式及预后
Aliment Pharmacol Ther. 2017 Nov;46(9):856-863. doi: 10.1111/apt.14261. Epub 2017 Aug 31.

引用本文的文献

1
Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses.肝癌中的新型基因改变可区分不同的临床结局和联合免疫治疗反应。
Front Pharmacol. 2024 Jun 14;15:1416295. doi: 10.3389/fphar.2024.1416295. eCollection 2024.
2
Hepatocellular carcinoma-the role of the underlying liver disease in clinical practice.肝细胞癌-基础肝病在临床实践中的作用。
World J Gastroenterol. 2024 May 21;30(19):2488-2495. doi: 10.3748/wjg.v30.i19.2488.
3
-derived short-chain fatty acids and indole compounds attenuate nonalcoholic fatty liver disease by modulating gut-liver axis.源自短链脂肪酸和吲哚化合物通过调节肠-肝轴减轻非酒精性脂肪性肝病。
Front Microbiol. 2023 Mar 1;14:1129904. doi: 10.3389/fmicb.2023.1129904. eCollection 2023.
4
MicroRNA-506-3p targets SIRT1 and suppresses AMPK pathway activation to promote hepatic steatosis.微小RNA-506-3p靶向沉默调节蛋白1并抑制AMPK信号通路激活以促进肝脂肪变性。
Exp Ther Med. 2021 Dec;22(6):1430. doi: 10.3892/etm.2021.10865. Epub 2021 Oct 11.
5
Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge.非酒精性脂肪性肝病中的肝细胞癌：一项日益严峻的挑战。
World J Hepatol. 2021 Sep 27;13(9):1107-1121. doi: 10.4254/wjh.v13.i9.1107.
6
Hepatocellular carcinoma in primary sclerosing cholangitis and primary biliary cholangitis: a clinical and pathological study in an uncommon but emerging setting.原发性硬化性胆管炎和原发性胆汁性胆管炎中的肝细胞癌：一种不常见但正在出现的情况下的临床和病理研究。
Virchows Arch. 2021 Dec;479(6):1131-1143. doi: 10.1007/s00428-021-03183-6. Epub 2021 Aug 20.
7
The cross-talk between DDR1 and STAT3 promotes the development of hepatocellular carcinoma.DDR1 和 STAT3 之间的串扰促进了肝癌的发展。
Aging (Albany NY). 2020 Jul 27;12(14):14391-14405. doi: 10.18632/aging.103482.

本文引用的文献

1
Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease.糖尿病与非酒精性脂肪性肝病相关肝硬化患者肝细胞癌风险增加相关。
Hepatology. 2020 Mar;71(3):907-916. doi: 10.1002/hep.30858. Epub 2019 Oct 21.
2
Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017.2007 年至 2017 年慢性肝病患者肝外并发症死亡率趋势。
Gastroenterology. 2019 Oct;157(4):1055-1066.e11. doi: 10.1053/j.gastro.2019.06.026. Epub 2019 Jun 25.
3
Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes.2 型糖尿病患者发生严重肝脏疾病的危险因素。
Clin Gastroenterol Hepatol. 2019 Dec;17(13):2769-2775.e4. doi: 10.1016/j.cgh.2019.04.038. Epub 2019 Apr 19.
4
Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.非肝硬化非酒精性脂肪性肝病患者肝细胞癌的特征和结局。
Liver Int. 2019 Jun;39(6):1098-1108. doi: 10.1111/liv.14087. Epub 2019 Mar 29.
5
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.全球视角下的非酒精性脂肪性肝病和非酒精性脂肪性肝炎。
Hepatology. 2019 Jun;69(6):2672-2682. doi: 10.1002/hep.30251.
6
The Way to the Liver Is Through the Pituitary Gland.通向肝脏的途径是通过垂体。
Am J Gastroenterol. 2018 Jan;113(1):145-146. doi: 10.1038/ajg.2017.434.
7
The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.非酒精性脂肪性肝病中肝细胞癌的故事：从流行病学、发病机制到预防与治疗。
Liver Int. 2016 Mar;36(3):317-24. doi: 10.1111/liv.13031. Epub 2015 Dec 25.
8
Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice.肝细胞癌：从流行病学到预防——将知识转化为实践
Clin Gastroenterol Hepatol. 2015 Nov;13(12):2140-51. doi: 10.1016/j.cgh.2015.08.014. Epub 2015 Aug 15.
9
Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells.JAK/STAT、PI3K/AKT和ERK信号的同时激活参与了瘦素介导的促进肝癌细胞侵袭和迁移的过程。
Cancer Res. 2007 Mar 15;67(6):2497-507. doi: 10.1158/0008-5472.CAN-06-3075.
10
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma.糖尿病会增加患慢性肝病和肝细胞癌的风险。
Gastroenterology. 2004 Feb;126(2):460-8. doi: 10.1053/j.gastro.2003.10.065.